Tackling chronic disease in Europe: strategies, interventions and challenges
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
World Health Organization. Regional Office for Europe
Abstract
Description
xiii, 111 p.
Chronic conditions and diseases are the leading cause of mortality and morbidity in Europe, accounting for 86% of total premature deaths, and research suggests that complex conditions such as diabetes and depression will impose an even greater health burden in the future. The epidemiologic and economic analyses in Part I of this book suggest that policy-makers should make chronic disease a priority. This book highlights the issues and focuses on the strategies and interventions that policy-makers have at their disposal to tackle this increasing challenge. Strategies discussed in Part II include prevention and early detection, new provider qualifications and settings, disease management programmes and integrated care models. But choosing the right strategies will be difficult, particularly given the limited evidence on effectiveness and cost-effectiveness. In Part III, the book therefore outlines and discusses institutional and organizational challenges for policy-makers and managers: stimulating the development of new effective pharmaceuticals and medical devices, designing appropriate financial incentives, improving coordination, using information and communication technology, and ensuring evaluation. To tackle these challenges successfully, key policy recommendations are made.
Chronic conditions and diseases are the leading cause of mortality and morbidity in Europe, accounting for 86% of total premature deaths, and research suggests that complex conditions such as diabetes and depression will impose an even greater health burden in the future. The epidemiologic and economic analyses in Part I of this book suggest that policy-makers should make chronic disease a priority. This book highlights the issues and focuses on the strategies and interventions that policy-makers have at their disposal to tackle this increasing challenge. Strategies discussed in Part II include prevention and early detection, new provider qualifications and settings, disease management programmes and integrated care models. But choosing the right strategies will be difficult, particularly given the limited evidence on effectiveness and cost-effectiveness. In Part III, the book therefore outlines and discusses institutional and organizational challenges for policy-makers and managers: stimulating the development of new effective pharmaceuticals and medical devices, designing appropriate financial incentives, improving coordination, using information and communication technology, and ensuring evaluation. To tackle these challenges successfully, key policy recommendations are made.